Fused ring pyrimidine amino compound and preparation method, pharmaceutical composition, and use thereof

US11655239B2 · kind B2 · utility

Assignee

• SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES · CN

Inventors

• Bing Xiong · Shanghai, CN
• Jia-He Li · Cockeysville, US
• Meiyu Geng · Shanghai, CN
• Jingkang Shen · Shanghai, CN
• Yi Zang · Princeton Junction, US
• Jing Ai · Shanghai, CN
• Danqi Chen · Shanghai, CN
• Qi Wang · Chesterfield, US
• Ying Dong · Eden Prairie, US
• Xia Peng · Shanghai, CN
• Yinchun JI · Shanghai, CN
• Qian TAN · Beijing, CN

Key dates

• Filing date: Jul 17, 2020
• Grant date: May 23, 2023
• Expiry date: Jul 17, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates to a fused ring pyrimidine amino compound and a preparation method, a pharmaceutical composition, and a use thereof. Specifically disclosed in the present disclosure are the compound shown in formula I, a pharmaceutically acceptable salt thereof, a tautomer thereof, a stereoisomer thereof, a metabolite thereof, a metabolic precursor thereof, or a prodrug thereof. The fused ring pyrimidine amino compound of the present application has good inhibitory activity against DDRs, particularly DDR2, and has a good therapeutic effect on tumors and fibrotic diseases, especially pulmonary inflammation and pulmonary fibrosis. Also disclosed in the present disclosure are a preparation method for the compound shown in formula I, and a use thereof.